CJC-1295 in Moores Pocket — GHRH Analog Research Guide
CJC-1295 research guide for Moores Pocket. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
CJC-1295 in Moores Pocket — Research & Sourcing Guide
Most researchers seeking out CJC-1295 in Moores Pocket rapidly learn that local retail options are essentially nonexistent. What this means for Moores Pocket researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are accessible to anyone. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. What follows is a vendor evaluation and quality guide built specifically around CJC-1295, covering everything a Moores Pocket researcher needs before placing a first order.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Moores Pocket comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Before looking at individual vendors, establish a quality benchmark — so you can tell whether a COA is complete and credible. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. Warning signs in CJC-1295 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that lack endotoxin data. Hold lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order CJC-1295 — ships to Moores Pocket
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — or 25mcg per insulin syringe unit. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, wrong peptide identity, and degraded material are all safety issues that rigorous vendor evaluation eliminates. Researchers combining CJC-1295 with other compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
